2-氧代-2-(2-氧代环戊基)乙酸乙酯 | 39163-39-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氧代-2-(2-氧代环戊基)乙酸乙酯
• 英文名称: oxo-(2-oxo-cyclopentyl)-acetic acid ethyl ester
• 英文别名: ethyl 2-oxo-2-(2-oxocyclopentyl)acetate
• CAS: 39163-39-8
• 化学式: C₉H₁₂O₄
• mdl: MFCD00019311
• 分子量: 184.192
• InChiKey: SYJZOWMPITUCHW-UHFFFAOYSA-N

物化性质

• 熔点：
  29 °C(Solv: pentane (109-66-0))
• 沸点：
  94-96 °C(Press: 0.1 Torr)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2918300090
• 危险性防范说明：
  P261,P272,P280,P302+P352,P321,P333+P313,P363,P501
• 危险性描述：
  H317
• 储存条件：
  室温、密封保存，并保持干燥。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Ethyl 4-methyl-2,3,5-trioxo-1-cyclopentaneglyoxylate
CAS-No. : 39163-39-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin sensitization (Category 1)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
May cause sensitization by skin contact.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H317 May cause an allergic skin reaction.
Precautionary statement(s)
P280 Wear protective gloves.
Supplemental Hazard none
Statements
May produce an allergic reaction.
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R43 May cause sensitization by skin contact.
S-phrase(s)
S36/37 Wear suitable protective clothing and gloves.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C9H12O4
Molecular Weight : 184,19 g/mol
Component Concentration
Ethyl 4-methyl-2,3,5-trioxo-1-cyclopentaneglyoxylate
CAS-No. 39163-39-8 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Indication of immediate medical attention and special treatment needed
no data available

---

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Precautions for fire-fighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use
respirators and components tested and approved under appropriate government standards such as
NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting/freezing point no data available
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 0,195
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
May cause allergic skin reaction.
The preceding data, or interpretation of data, was determined using Quantitative Structure Activity
Relationship (QSAR) modeling.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional
waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent
and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN-Number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for users
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氧代-2-(2-氧代环戊基)乙酸乙酯 在 肼 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以16.16 g的产率得到1,4,5,6-四氢-3-环戊二烯并吡唑羧基酸乙酯
  参考文献：
  名称：

  3-(1H-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice

  摘要：

  The discovery and profiling of 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopeiitapyrazole (5a, MK-0354), a partial agonist of GPR 109a, is described. Compound 5a retained the plasma free fatty acid lowering effects in mice associated with GPR109a agonism, but did not induce vasodilation at the maximum feasible dose. Moreover, preadministration of 5a blocked the flushing effect induced by nicotinic acid but not that induced by PGD(2). This profile made 5a a suitable candidate for further study for the treatment of dyslipidemia.

  DOI：

  10.1021/jm800258p
• 作为产物：
  描述：

  环戊酮 、 草酸二乙酯 在 氢氧化钾 作用下， 以 四氢呋喃 为溶剂， 生成 2-氧代-2-(2-氧代环戊基)乙酸乙酯
  参考文献：
  名称：

  6-氧代取代的螺-吡咯烷二酮的开环反应：4-取代的1,5-二氢-3-羟基-2-氧-2-氧-1,5-二苯基-2 H-吡咯的合成

  摘要：

  2-氧代羰基烷氧基甲酸酯与N-苯基亚甲基苯胺反应生成螺环化合物，例如2-氮杂-3,4,6，-三氧代-1,2-二苯基螺[4.4]壬烷4和环烷-2-氮杂-3,4,6 -trioxo-1,2，diphenylspiro- [4.5]癸烷5-7。它们经历氧代环烷烃环的溶剂化开放，从而产生4-取代的1,5-二氢-3-羟基-2-氧代-1,5-二苯基-2 H-吡咯12-17。

  DOI：

  10.1002/jhet.5570350320

文献信息

• [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS D'ALCYNYLE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015025025A1

  公开（公告）日：2015-02-26

  The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.

  这项发明涉及以下式的化合物（0）：其中Q，A1-A8，R4和R5分别具有如本文所述的含义。式（0）的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度活化的疾病和紊乱中是有用的。
• Synthesis of Functionalized Cyclobutenes and Spirocycles <i>via</i> Asymmetric P(III)/P(V) Redox Catalysis
  作者：Charlotte Lorton、Antoine Roblin、Pascal Retailleau、Arnaud Voituriez

  DOI：10.1002/adsc.202100664

  日期：2021.10.19

  phosphine-catalyzed transformation has been developed for the synthesis of chiral cyclobutene triesters and fluorinated spirocyclic compounds. The strategy involved a P(III)/P(V) redox cycling process, via in situ reduction of phosphine oxide with phenylsilane. This catalytic methodology has enabled the enantioselective synthesis of functionalized cyclobutenes (24 examples, up to 94% ee). On the occasion of the

  已开发出一种对映选择性膦催化转化，用于合成手性环丁烯三酯和氟化螺环化合物。该策略涉及 P(III)/P(V) 氧化还原循环过程，通过用苯基硅烷原位还原氧化膦。这种催化方法使官能化环丁烯的对映选择性合成成为可能（24 个例子，高达 94% ee）。在将这项研究扩展到 α-酮酯茚酮底物时，发现了合成螺茚酮产物的惊人反应性。
• [DE] NEUE CARBONSÄUREAMIDE, DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS<br/>[FR] NOUVEAUX AMIDES D'ACIDE CARBOXYLIQUE, LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004056784A1

  公开（公告）日：2004-07-08

  Gegenstand der vorliegenden Erfindung sind neue substituierte Carbonsäureamide der allgemeinen Formel (I), in der A, B und R1 bis R5 wie in Anspruch 1 definiert sind, deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle Eigenschaften aufweisen. Die Verbindungen der obigen allgemeinen Formel (I) sowie deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, und deren Stereoisomere weisen wertvolle pharmakologische Eigenschaften auf, insbesondere eine antithrombotische Wirkung und eine Faktor Xa-inhibierende Wirkung.

  本发明涉及一种新的取代羧酰胺，其通式为(I)，其中A、B和R1至R5如权利要求1所定义，其互变异构体、对映异构体、非对映异构体、混合物和盐，特别是其与无机或有机酸或碱形成的生理相容盐，具有有价值的特性。上述通式(I)的化合物及其互变异构体、对映异构体、非对映异构体、混合物和盐，特别是其与无机或有机酸或碱形成的生理相容盐，以及其立体异构体具有有价值的药理特性，特别是抗血栓作用和Xa因子抑制作用。
• Antithrombotic carboxylic acid amides
  申请人：——

  公开号：US20020183519A1

  公开（公告）日：2002-12-05

  Carboxylic acid amides of formula 1 having antithrombotic activity and a factor Xa-inhibiting activity. Exemplary are: 2-(5-amidino-2-hydroxy-phenyl)-N-[3-methyl-4-(2-tert-butoxycarbonylaminomethyl -benzimidazol-1-yl)-phenyl]-acetamide; 2-(5-amidino-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminomethyl-benzimidazol-1-yl)-phenyl]-acetamide; and 2-(5-amidino-2-hydroxy-phenyl)-N-[4-(4,5-dimethyl-2-oxo-2,3-dihydroimidazol-1-yl) -3-methyl-phenyl]-acetamide.

  公式1的羧酸酰胺具有抗血栓活性和Xa因子抑制活性。例如：2-(5-酰胺基-2-羟基苯基)-N-[3-甲基-4-(2-叔丁氧羰胺甲基-苯并咪唑-1-基)-苯基]-乙酰胺；2-(5-酰胺基-2-羟基苯基)-N-[3-甲基-4-(2-氨基甲基-苯并咪唑-1-基)-苯基]-乙酰胺；以及2-(5-酰胺基-2-羟基苯基)-N-[4-(4,5-二甲基-2-氧代-2,3-二氢咪唑-1-基)-3-甲基-苯基]-乙酰胺。
• [EN] SUBSTITUTED BICYCLIC COMPOUNDS AS INHIBITORS OF EZH2<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS D'EZH2
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2014155301A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of formula 1, isotopic forms, stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, solvates, N-oxides, S-oxides and polymorphs thereof, and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.

  本发明提供了公式1的化合物，其同位素形式、立体异构体或互变异构体，或其药用可接受的盐、溶剂化合物、N-氧化物、S-氧化物和多晶形式，以及其制备方法。本发明还涉及含有所述化合物的药物组合物，并其在治疗由EZH2（zeste同源物增强子2）介导的疾病或紊乱中的应用，特别是癌症。